Prosecution Insights
Last updated: October 25, 2026

Jc One World

Technology area: Biotechnology & Pharmaceuticals

13 pending office actions • 9 clients • 12 examiners • 12 art units • 0 of 13 (0%) have an AI response strategy ready • 30 patents granted in the last 365 days

Analysis

JC ONE WORLD has 13 pending office actions in Biotechnology & Pharmaceuticals. Its career record includes 180 applications, providing historical context for prosecution in this technology area.

The resolved allowance rate is 95.83%, and the average is 1.3 office actions per allowance. The profile therefore offers separate indicators of historical outcome and examination effort, while the pending docket identifies current matters still in prosecution.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=180 apps, methodology: how we score firms)

95.8%
Allowance Rate
n=180
+0.65σ
Allowance Rate (norm)
n=180
1.3
OAs to Allowance
n=46
-1.29σ
OAs to Allow (norm)
n=46
718 days
Time to Allowance
n=46
+5.7pp
Interview Lift
n=180
10.4%
RCE Rate
n=180
0.0%
Appeal Rate
n=180

Rejection Performance (% of received rejections ultimately overcome)

—
§101 Overcome
n=14 (min 20)
—
§102 Overcome
n=15 (min 20)
35.0%
§103 Overcome
n=20
55.6%
§112 Overcome
n=27

Specialization & Scale

A61K, A61P, C12N
Top CPC Subclasses
26%
Top-3 CPC Share
n=180
0
Practitioners
n=180
—
Apps / Practitioner
n=180 (min 20)

Portfolio Summary

13
Total Pending OAs
12
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

9
Hard (69%)
3
Medium (23%)
1
Easy (8%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only1 (8%)
§101 + other4 (31%)
§103 only2 (15%)
§102 only1 (8%)
§112 only1 (8%)
Multi-statute (no §101)4 (31%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

8
Life Sciences
62% of docket
0
Information Tech
0% of docket
1
Communications
8% of docket
2
Semiconductors
15% of docket
2
Mechanical / Eng
15% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

130 h
Manual time on pending OAs
26 h
Time saved (low, 20%)
46 h
Time saved (mid, 35%)
1.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
TATGE, LEXUS MARC 2 25.0% +100.0%
TORRICO-LOPEZ, ALAN 1 29.3% +37.3%
DAGNEW, MEKONNEN D 1 83.6% +15.4%
MUIR, MATTHEW SINCLAIR 1 70.9% +29.4%
YOUNG, EDWIN 1 91.5% +5.9%
SHARMA, ADITYA 1 78.0% +29.5%
AUDET, MAURY A 1 50.1% +23.9%
ABBOTT, KODYE LEE 1 54.5% +71.4%
MOORE, JOHN DAVID 1 61.1% +28.3%
PETRASH, HILARY ANN 1 65.6% +50.2%

Quick Wins (2)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
19001419 METHOD OF DETECTING A DEFOCUS OF AN IMAGE SENSOR AND IMAGE SENSOR DAGNEW, MEKONNEN D —
18862175 ACTIVE AIR INTAKE GRILLE AND VEHICLE YOUNG, EDWIN —

Hard Cases (9)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18834230 METHOD FOR GRADING SUITABLE CONSTRUCTION RANGE BASED ON COLD ISLAND VALUE EVALUATION TORRICO-LOPEZ, ALAN —
18867446 UNIFORM-TEMPERATURE RADIATOR WITH MULTI-FLOW CHANNEL MUIR, MATTHEW SINCLAIR —
18650037 USE OF PROTEIN SEQUENCE CAPABLE OF BINDING TO SUBSTRATE IN PREPARATION OF PRODUCT FOR INHIBITING FIBRIN ASSEMBLY AUDET, MAURY A —
18592249 APPLICATION OF GENETICALLY MODIFIED OLIGODENDROCYTE PROGENITOR CELLS IN MULTIPLE SCLEROSIS ABBOTT, KODYE LEE —
18433083 RAPID AND EFFICIENT CLINICAL GRADE PIGMENT EPITHELIUM INDUCTION METHOD, KIT, AND APPLICATION MOORE, JOHN DAVID —
18415188 COMPOSITIONS AND METHODS FOR TREATING ACUTE MYELOID LEUKEMIA PETRASH, HILARY ANN —
18374236 GENE CIRCUIT, RNA DELIVERY SYSTEM AND USE THEREOF TATGE, LEXUS MARC —
18373605 NUCLEIC ACID DELIVERY SYSTEM AND APPLICATION THEREOF TATGE, LEXUS MARC —

Interview Candidates (10)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18834230 METHOD FOR GRADING SUITABLE CONSTRUCTION RANGE BASED ON COLD ISLAND VALUE EVALUATION TORRICO-LOPEZ, ALAN —
19001419 METHOD OF DETECTING A DEFOCUS OF AN IMAGE SENSOR AND IMAGE SENSOR DAGNEW, MEKONNEN D —
18867446 UNIFORM-TEMPERATURE RADIATOR WITH MULTI-FLOW CHANNEL MUIR, MATTHEW SINCLAIR —
18857819 LOW-INDUCTANCE CURRENT-SHARING POWER MODULE SHARMA, ADITYA —
18650037 USE OF PROTEIN SEQUENCE CAPABLE OF BINDING TO SUBSTRATE IN PREPARATION OF PRODUCT FOR INHIBITING FIBRIN ASSEMBLY AUDET, MAURY A —
18592249 APPLICATION OF GENETICALLY MODIFIED OLIGODENDROCYTE PROGENITOR CELLS IN MULTIPLE SCLEROSIS ABBOTT, KODYE LEE —
18433083 RAPID AND EFFICIENT CLINICAL GRADE PIGMENT EPITHELIUM INDUCTION METHOD, KIT, AND APPLICATION MOORE, JOHN DAVID —
18415188 COMPOSITIONS AND METHODS FOR TREATING ACUTE MYELOID LEUKEMIA PETRASH, HILARY ANN —

Client Portfolio (9 clients)

Top Art Units

Art UnitApps
16372
36251
26381
28411
36551
28471
16541
16341
16381
16441

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18834230 METHOD FOR GRADING SUITABLE CONSTRUCTION RANGE BASED ON COLD ISLAND VALUE EVALUATION Architecs & Engineers Co., Ltd. Of Southeast University TORRICO-LOPEZ, ALAN 3625 §101 Non-Final OA — Pending Sep 18, 2025
19001419 METHOD OF DETECTING A DEFOCUS OF AN IMAGE SENSOR AND IMAGE SENSOR Omnivision Technologies, Inc. DAGNEW, MEKONNEN D 2638 §103 Non-Final OA — Pending Dec 25, 2024
18867446 UNIFORM-TEMPERATURE RADIATOR WITH MULTI-FLOW CHANNEL Yangzhou Guoyang Electronic Co., Ltd. MUIR, MATTHEW SINCLAIR 2841 §103§112 Non-Final OA — Pending Nov 20, 2024
18862175 ACTIVE AIR INTAKE GRILLE AND VEHICLE Wuhan Lotus Cars Co., Ltd. YOUNG, EDWIN 3655 §102 Final Rejection — Pending Nov 01, 2024
18857819 LOW-INDUCTANCE CURRENT-SHARING POWER MODULE Yangzhou Guoyang Electronic Co., Ltd. SHARMA, ADITYA 2847 §103 Non-Final OA — Pending Oct 18, 2024
18650037 USE OF PROTEIN SEQUENCE CAPABLE OF BINDING TO SUBSTRATE IN PREPARATION OF PRODUCT FOR INHIBITING FIBRIN ASSEMBLY Huazhong Agricultural University AUDET, MAURY A 1654 §101§112 Non-Final OA — Pending Apr 29, 2024
18592249 APPLICATION OF GENETICALLY MODIFIED OLIGODENDROCYTE PROGENITOR CELLS IN MULTIPLE SCLEROSIS Allife Medicine (Beijing) Limited ABBOTT, KODYE LEE 1634 §103§112 Non-Final OA — Pending Feb 29, 2024
18433083 RAPID AND EFFICIENT CLINICAL GRADE PIGMENT EPITHELIUM INDUCTION METHOD, KIT, AND APPLICATION Allife Medicine (Zhuhai) Limited MOORE, JOHN DAVID 1638 §102§103§112 Non-Final OA — Pending Feb 05, 2024
18415188 COMPOSITIONS AND METHODS FOR TREATING ACUTE MYELOID LEUKEMIA Wuhan University PETRASH, HILARY ANN 1644 §101§102§103§112 Non-Final OA — Pending Jan 17, 2024
18521956 METHOD FOR DIFFERENTIATING HUMAN INDUCED PLURIPOTENT STEM CELLS INTO OLIGODENDROCYTES, AND KIT AND USE Allife Medicine (Zhuhai) Limited BATES, KEENAN ALEXANDER 1631 §112 Non-Final OA — Pending Nov 28, 2023
18374236 GENE CIRCUIT, RNA DELIVERY SYSTEM AND USE THEREOF Nanjing University TATGE, LEXUS MARC 1637 §101§102§112DP Non-Final OA — Pending Sep 28, 2023
18373605 NUCLEIC ACID DELIVERY SYSTEM AND APPLICATION THEREOF Nanjing University TATGE, LEXUS MARC 1637 §101§102§103§112DP Non-Final OA — Pending Sep 27, 2023
18271654 COMPOSITIONS AND METHODS FOR INSTANT NUCLEIC ACID DETECTION Wuhan University HANEY, AMANDA MARIE 1682 §102§103§112 Non-Final OA — Pending Jul 10, 2023

Managing Jc One World's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

What is Jc One World's patent allowance rate?

95.8% of resolved applications prosecuted by Jc One World were allowed, across 180 applications in USPTO records.

How many office actions does Jc One World average before allowance?

1.30 office actions per allowed application on average.

How many pending office actions does Jc One World have?

13 pending office actions as of October 2026, for 9 clients, before 12 examiners in 12 art units.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month